Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27735639 | 0.80 | HCAR2 (0.42) | HCAR2TSHRCA12AKR1B10CA1 | |
| SCHEMBL131152 | 0.78 | — | — | |
| SCHEMBL27563649 | 0.78 | — | — | |
| SCHEMBL125807 | 0.78 | — | — | |
| SCHEMBL131028 | 0.77 | HCAR2 (0.43) | HCAR2TSHRCA12AKR1B10CA1 | |
| SCHEMBL2412135 | 0.76 | — | — | |
| SCHEMBL127506 | 0.74 | HCAR2 (0.45) | HCAR2TSHRCA12AKR1B10CA1 | |
| SCHEMBL128626 | 0.74 | TSHR (0.59) | TSHRGRIK1ALDH1A1TDP1 | |
| SCHEMBL128591 | 0.74 | HCAR2 (0.45) | HCAR2TSHRCA12CA1CA2 | |
| SCHEMBL26129546 | 0.74 | TDP1 (0.46) | TSHRGRIK1ALDH1A1CYP3A4TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109641904-B | 7-substituted sulfoxy-purinone compounds for the treatment and prevention of viral infections | 豪夫迈·罗氏有限公司 | 2022-01-28 | — | — | CN | claimed |
| EP-3504210-B1 | 7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2021-02-24 | — | — | EP | claimed |
| EP-3758707-A1 | 7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS AND DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF LIVER CANCER | F. Hoffmann-La Roche AG (CH) | 2021-01-06 | — | — | EP | claimed |
| US-20200385387-A1 | 7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS FOR THE TREATMENT OF VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2020-12-10 | — | — | US | claimed |
| CN-111801100-A | 7-substituted sulfoxy-purinone compounds and derivatives for the treatment and prevention of liver cancer | 豪夫迈·罗氏有限公司 | 2020-10-20 | — | — | CN | claimed |
| US-20200268762-A1 | 7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS AND DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF LIVER CANCER | HOFFMANN-LA ROCHE INC. (US) | 2020-08-27 | — | — | US | claimed |
| US-10752630-B2 | 7-substituted sulfonimidoylpurinone compounds for the treatment of virus infection | HOFMANN LA-ROCHE INC. (US) | 2020-08-25 | — | — | US | claimed |
| US-20190256515-A1 | NOVEL SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS AND DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2019-08-22 | — | — | US | claimed |
| EP-3504210-A1 | 7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION | H. Hoffnabb-La Roche Ag (CH) | 2019-07-03 | — | — | EP | claimed |
| US-10233184-B2 | 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection | HOFFMANN-LA ROCHE INC. (US) | 2019-03-19 | — | — | US | claimed |
| US-20180072730-A1 | NOVEL 7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS AND DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2018-03-15 | — | — | US | claimed |
| WO-2018041763-A1 | 7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2018-03-08 | — | — | WO | claimed |
| EP-0188805-B1 | 1,3-DITHIOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1989-09-06 | — | — | EP | claimed |
| EP-0188805-A1 | 1,3-Dithiole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1986-07-30 | — | — | EP | claimed |
| CN-111801100-B | 7-substituted sulfoimidoyl purinone compounds and derivatives for the treatment and prevention of liver cancer | 豪夫迈·罗氏有限公司 | 2023-10-24 | — | — | CN | disclosed |
| CN-109641904-B | 7-substituted sulfoxy-purinone compounds for the treatment and prevention of viral infections | 豪夫迈·罗氏有限公司 | 2022-01-28 | — | — | CN | disclosed |
| EP-3865482-A1 | 7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2021-08-18 | — | — | EP | disclosed |
| EP-1982986-B1 | PYRROLOPYRIDAZINONE COMPOUND AS PDE4 INHIBITOR | UBE INDUSTRIES (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20090036453-A1 | Pyrrolopyridazinone Compound | UBE INDUSTRIES, LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
| EP-1982986-A1 | PYRROLOPYRIDAZINONE COMPOUND | Ube Industries, Ltd. (JP) | 2008-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10752630-B2 | 7-substituted sulfonimidoylpurinone compounds for the treatment of virus infection | FURIN, UGT1A7, SARS1 | HCAR2 4521/4885TSHR 4339/4885CA12 2511/4885 |
| US-20190256515-A1 | NOVEL SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS AND DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION | TPMT, SULT1E1, SULT1A1 | HCAR2 4042/4885TSHR 4350/4885CA12 2787/4885 |
| US-20200385387-A1 | 7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS FOR THE TREATMENT OF VIRUS INFECTION | FURIN, UGT1A7, SARS1 | HCAR2 4521/4885TSHR 4339/4885CA12 2511/4885 |
| US-20200268762-A1 | 7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS AND DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF LIVER CANCER | SULT1E1, SULT1A1, UGT2B7 | HCAR2 3092/4885TSHR 4071/4885CA12 2396/4885 |
| US-20180072730-A1 | NOVEL 7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS AND DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION | TPMT, SULT1E1, UGT1A7 | HCAR2 4021/4885TSHR 4523/4885CA12 2576/4885 |
| US-20090036453-A1 | Pyrrolopyridazinone Compound | CBR3, CBR1, CYC1 | HCAR2 99/4885TSHR 1420/4885CA12 2239/4885 |
| US-10233184-B2 | 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection | TPMT, UGT1A7, UGT2B7 | HCAR2 4091/4885TSHR 4538/4885CA12 3221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.